Adherium (ASX:ADR) has officially launched its Hailie solution in the US following its recent approval by the Food and Drug Administration for over-the-counter sales direct to consumers.
Hailie is designed to help patients with asthma and COPD to access better care through a digital experience that includes a smartphone app, available on both iOS and Android, and a sensor that attaches to patient’s prescription inhaler medication.
Adherium said Hailie tracks medication use and reminds the user when it is time to take doses. It can also provide visibility of medication use and adherence to parents and caregivers.
“We’re extremely excited to announce the availability of the full Hailie solution in the US,” said Arik Anderson, CEO of Adherium.
“Individuals and families with asthma and COPD can now access a solution that encompasses the world’s most clinically proven asthma and COPD medication adherence platform, cleverly packaged into the simplest interface.
"Hailie is the culmination of 15 years of accelerating research and development and is focused on the premise that if we are to turn the corner on treating chronic conditions, we have to make managing them second nature. Today, through advances in technology, the power of real-time feedback, and data science we can cross that last mile in achieving better health –putting medicine to work in the proving ground of everyday life.”
Adherium announced it is also launching an online portal for healthcare professionals and clinicians (go.hailie.com) to visualise and analyse patient-group data collected from Hailie sensors.
Adherium said it has sold more than 130,000 inhaler sensors globally.